Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
189 hedge funds and large institutions have $1.38B invested in Impax Laboratories, Inc. in 2017 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 68 increasing their positions, 50 reducing their positions, and 17 closing their positions.
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
36% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 50
32% more capital invested
Capital invested by funds: $1.05B → $1.38B (+$334M)
21% more call options, than puts
Call options by funds: $2.8M | Put options by funds: $2.31M
10% more funds holding
Funds holding: 172 → 189 (+17)
3.32% more ownership
Funds ownership: 88.05% → 91.37% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
+$68M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
+$28.6M |
| 3 |
Janus Henderson Group
London,
|
+$26.9M |
| 4 |
Goldman Sachs
New York
|
+$24.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$19.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$37.3M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$22.3M |
| 3 |
NTC
North Tide Capital
Boston,
Massachusetts
|
-$16.1M |
| 4 |
BM
Bridger Management
New York
|
-$14.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.1M |
IPXL Hedge Fund Activity: Q3 2017 in Review
189 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q3 2017, worth a combined $1.38B — up 32% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new IPXL positions and 17 closed out — a net gain of 20 holders — while 68 added to existing stakes and 50 trimmed.
The largest buyer was Fosun International, adding an estimated $68M. The largest seller was Citadel Advisors, cutting an estimated $37.3M.
- 189 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q3 2017, up from 172 in Q2 2017.
- Funds reported $1.38B of Impax Laboratories, Inc. stock for Q3 2017, up 32% quarter-over-quarter.
- 37 funds opened new Impax Laboratories, Inc. positions in Q3 2017 and 17 closed out, a net change of +20 holders.
- The largest Impax Laboratories, Inc. buyer in Q3 2017 was Fosun International, an estimated $68M added.
- The largest Impax Laboratories, Inc. seller in Q3 2017 was Citadel Advisors, an estimated $37.3M sold.
Based on aggregated 13F filings for Q3 2017.